Log In
BCIQ
Print this Print this
 

GSK2878175

  Manage Alerts
Collapse Summary General Information
Company GlaxoSmithKline plc
DescriptionNon-nucleoside HCV NS5B polymerase inhibitor
Molecular Target HCV NS5B polymerase
Mechanism of ActionHCV non-structural protein 5B inhibitor
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard IndicationHepatitis C virus (HCV)
Indication DetailsTreat HCV genotypes 1 and 3 infection in treatment-naïve patients
Regulatory Designation
PartnerRegulus Therapeutics Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

11/03/2015

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today